Starling Oncology director Hively to leave board in 2027
Starling Oncology, Inc. (STLN) reported a board-level change.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Starling Oncology, Inc. (STLN) reported a board-level change. On September 1, 2026, director Brad Hively notified the company that he will not stand for re-election to the Board at the 2027 annual meeting of stockholders. He is expected to remain a director until that meeting but, effective immediately, no longer serves as Vice Chairman of the Board or as a member of the Compliance Committee or any other board committees. The company states that his decision is not due to any disagreement regarding its operations, policies, or practices.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Common stock par value: $0.0001 per share
Warrant exercise price: $11.50 per share
Commission File Number: 001-39248
3 metrics
Common stock par value
$0.0001 per share
Par value of Starling Oncology, Inc. common stock registered under Section 12(b)
Warrant exercise price
$11.50 per share
Each redeemable warrant exercisable for one share of common stock
Commission File Number
001-39248
Starling Oncology, Inc. registration under the Exchange Act
Key Terms
Redeemable warrants, Emerging growth company, Compliance Committee, Exchange Act
4 terms
Redeemable warrants financial
"Redeemable warrants, each whole warrant exercisable for one share of Common stock"
A redeemable warrant is a tradable right that lets its holder buy a company’s shares at a fixed price before a set date, but the issuer has the contract power to cancel (redeem) the warrant early under agreed terms. For investors this matters because early redemption can force decision-making, change the timing of when new shares might be created, and affect potential gains or dilution—much like a store coupon that the issuer can cancel by paying you off instead of letting you use it.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Compliance Committee regulatory
"no longer serve as Vice Chairman of the Board or as a member of the Compliance Committee"
Exchange Act regulatory
"pursuant to Rule 14a-12 under the Exchange Act"
A federal law that sets rules for trading securities on public exchanges, requiring companies and market participants to register, disclose regular financial information, and follow standards that promote honest, orderly markets. For investors, it matters because it creates transparency and legal protections—like stopping insider trading and ensuring timely company disclosures—so you can evaluate risks and rely on consistent rules much as players rely on a referee to keep a game fair.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What board change did Starling Oncology, Inc. (STLN) announce on September 1, 2026?
Starling Oncology, Inc. announced that director Brad Hively will not stand for re-election at the 2027 annual meeting. He will remain on the Board until that meeting but has resigned immediately as Vice Chairman and from the Compliance Committee and all other board committees.
When will Brad Hively leave the Board of Starling Oncology (STLN)?
Brad Hively is expected to continue serving as a director of Starling Oncology, Inc. until the company’s 2027 annual meeting of stockholders, after which he will depart the Board because he has chosen not to stand for re-election at that meeting.
What positions did Brad Hively relinquish immediately at Starling Oncology (STLN)?
Effective immediately as of September 1, 2026, Brad Hively no longer serves as Vice Chairman of the Board of Starling Oncology, Inc. and is no longer a member of the Compliance Committee or any other committees of the Board.
Did Brad Hively cite any disagreement with Starling Oncology (STLN) for not standing for re-election?
Starling Oncology, Inc. states that Brad Hively’s decision not to stand for re-election to the Board is not the result of any disagreement with the company regarding its operations, policies, or practices.
Who signed the September 1, 2026 Form 8-K for Starling Oncology, Inc. (STLN)?
The Form 8-K dated September 1, 2026 for Starling Oncology, Inc. was signed by Minh Merchant, who is identified as the company’s Chief Legal Officer.
On which exchange is Starling Oncology, Inc. (STLN) listed and what securities trade there?
Starling Oncology, Inc.’s common stock and redeemable warrants trade on The Nasdaq Stock Market LLC. The common stock trades under the symbol STLN, and the redeemable warrants trade under the symbol TOIIW.
AI-generated analysis. How Rhea-AI works. Not financial advice.
